During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
Dividend Yield: 6.57%
Citigroup analyst Geoff Meacham maintained a Neutral rating and raised the price target from $26 to $27 on April 29, 2026. This analyst has an accuracy rate of 70%.
RBC Capital analyst Trung Huynh maintained an Underperform rating while also maintaining the price target at $25 on April 20, 2026. This analyst has an accuracy rate of 69%.
Recent News: On May 29, Pfizer signed a cancer drug development deal worth $10.5 billion with Innovent Biologics.
Benzinga Pro’s real-time newsfeed alerted to latest NOG news.
DENTSPLY SIRONA Inc (NASDAQ:XRAY)
Dividend Yield: 6.05%
UBS analyst Kevin Caliendo maintained a Buy rating and cut the price target from $18 to $17 on May 7, 2026. This analyst has an accuracy rate of 68%.
Mizuho analyst Steven Valiquette maintained a Neutral rating and cut the price target from $16 to $14 on May 6, 2026. This analyst has an accuracy rate of 52%.
Recent News: On May 26, Dentsply Sirona partnered with Nashville Dental, Inc to expand its U.S. distribution network.
Benzinga Pro's real-time newsfeed alerted to latest PAGP news
Bristol-Myers Squibb Co (NYSE:BMY)
Dividend Yield: 4.42%
Guggenheim analyst Seamus Fernandez maintained a Buy rating and the price target at $72 on April 8, 2026. This analyst has an accuracy rate of 75%.
Cantor Fitzgerald analyst Carter Gould maintained a Neutral rating and increased the price target from $45o $54 on April 8, 2026. This analyst has an accuracy rate of 62%.
Recent News: On May 20, Bristol-Myers Squibb announced an agreement with Anthropic to deploy Claude across its research, clinical development, manufacturing, commercial, and corporate functions.
Benzinga Pro’s real-time newsfeed alerted to latest ET news
Login to comment